A Single Arm, Open-Label, Phase 2 Study of Melflufen in Combination with Dexamethasone in Patients with Relapsed Refractory Multiple Myeloma who are Refractory to Pomalidomide and/or Daratumumab.

Trial Profile

A Single Arm, Open-Label, Phase 2 Study of Melflufen in Combination with Dexamethasone in Patients with Relapsed Refractory Multiple Myeloma who are Refractory to Pomalidomide and/or Daratumumab.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs Dexamethasone (Primary) ; Melphalan flufenamide (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms HORIZON
  • Sponsors Oncopeptides
  • Most Recent Events

    • 16 Nov 2016 Status changed from not yet recruiting to recruiting.
    • 09 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top